CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload ...

CE-Ventures, the corporate venture capital arm of the UAE-based investment firm Crescent Enterprises, has announced that its ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

Eli Lilly, the maker of the popular GLP-1 injectable Mounjaro, has invested heavily in Houston as a biotechnology hub.

CrossBridge Bio develops a dual-payload ADC technology created by Kyoji Tsuchikama at the University of Texas Health Science ...

Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” ...

Preview this article 1 min CrossBridge Bio is developing unique methods to transport chemotherapy to cancer cells, and its ...

Linden Lake Labs ("L3"), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio, has entered into a definitive ...

HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million ...

CrossBridge Bio, a biotechnology company developing next-generation antibody-drug conjugates based on discoveries by ...

CE-Ventures, the corporate venture capital arm of Crescent Enterprises, on Tuesday announced that its portfolio company CrossBridge Bio has entered into a definitive agreement to be acquired by US pha ...

CrossBridge Bio’s innovative approach to create stable, multi-loaded antibody–drug conjugates is set to generate a suite of first-in-class and best-in-class cancer therapies. Antibody–drug conjugates ...